Phase II Trial of Osimertinib in Combination With Stereotactic Ablative Radiation (SABR) in EGFR Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Apr 2019 Planned number of patients changed from 27 to 37.
- 28 Dec 2018 Status changed from not yet recruiting to recruiting.
- 19 Sep 2018 New trial record